| scholarly article | Q13442814 |
| P50 | author | Robert L Ferris | Q38328358 |
| Tatiana M Garcia-Bates | Q56494396 | ||
| P2093 | author name string | Tania Crombet | |
| Fernando Concha-Benavente | |||
| Raghvendra M Srivastava | |||
| Zaima Mazorra | |||
| Iván Cuevas | |||
| Amnely González | |||
| Anabel Lavastida | |||
| Anet Valdés | |||
| Braulio F Mestre | |||
| Carlos Frómeta | |||
| Esperanza Hechavarría | |||
| Maria C Barroso | |||
| Martha Lugiollo | |||
| Zuyen González | |||
| P2860 | cites work | Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin | Q24645217 |
| Interactions between PD-1 and PD-L1 promote tolerance by blocking the TCR-induced stop signal. | Q24655516 | ||
| Nimotuzumab, an antitumor antibody that targets the epidermal growth factor receptor, blocks ligand binding while permitting the active receptor conformation | Q27656338 | ||
| Interaction of Tim-3 and Tim-3 ligand regulates T helper type 1 responses and induction of peripheral tolerance | Q28511160 | ||
| Reversal of NK-cell exhaustion in advanced melanoma by Tim-3 blockade | Q33714165 | ||
| Targeting CD137 enhances the efficacy of cetuximab. | Q33872482 | ||
| The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity | Q34073138 | ||
| 4-1BB (CD137), an inducible costimulatory receptor, as a specific target for cancer therapy | Q34180031 | ||
| Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape | Q34194706 | ||
| Humanization of a mouse monoclonal antibody that blocks the epidermal growth factor receptor: recovery of antagonistic activity | Q34426559 | ||
| CD137 stimulation enhances the antilymphoma activity of anti-CD20 antibodies | Q34707604 | ||
| CTLA-4⁺ Regulatory T Cells Increased in Cetuximab-Treated Head and Neck Cancer Patients Suppress NK Cell Cytotoxicity and Correlate with Poor Prognosis | Q35674757 | ||
| Stimulation of natural killer cells with a CD137-specific antibody enhances trastuzumab efficacy in xenotransplant models of breast cancer | Q35780315 | ||
| In vitro analysis of the proliferative capacity and cytotoxic effects of ex vivo induced natural killer cells, cytokine-induced killer cells, and gamma-delta T cells | Q35803534 | ||
| Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9 | Q35876978 | ||
| Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity | Q35909663 | ||
| Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck | Q36500969 | ||
| Fc-dependent expression of CD137 on human NK cells: insights into "agonistic" effects of anti-CD137 monoclonal antibodies | Q36787500 | ||
| Cetuximab-activated natural killer and dendritic cells collaborate to trigger tumor antigen-specific T-cell immunity in head and neck cancer patients | Q36806268 | ||
| TIM3(+)FOXP3(+) regulatory T cells are tissue-specific promoters of T-cell dysfunction in cancer | Q36845835 | ||
| Novel immunogenic HLA-A*0201-restricted epidermal growth factor receptor-specific T-cell epitope in head and neck cancer patients | Q36962838 | ||
| Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer | Q37369840 | ||
| Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer | Q37373689 | ||
| Tim-3: an activation marker and activation limiter of innate immune cells | Q37379212 | ||
| PD-1 mediates functional exhaustion of activated NK cells in patients with Kaposi sarcoma | Q37687323 | ||
| Natural killer (NK): dendritic cell (DC) cross talk induced by therapeutic monoclonal antibody triggers tumor antigen-specific T cell immunity | Q37895956 | ||
| Nimotuzumab treatment of malignant gliomas | Q38050155 | ||
| Enhanced natural killer cell binding and activation by low-fucose IgG1 antibody results in potent antibody-dependent cellular cytotoxicity induction at lower antigen density | Q38328896 | ||
| Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations | Q38475048 | ||
| PD-1 expression on peripheral blood cells increases with stage in renal cell carcinoma patients and is rapidly reduced after surgical tumor resection. | Q39143622 | ||
| IgG isotype, glycosylation, and EGFR expression determine the induction of antibody-dependent cellular cytotoxicity in vitro by cetuximab | Q39617025 | ||
| Bivalent binding by intermediate affinity of nimotuzumab: a contribution to explain antibody clinical profile | Q39621039 | ||
| Long-lasting antitumor protection by anti-CD20 antibody through cellular immune response | Q39707969 | ||
| The impact of antigen density and antibody affinity on antibody-dependent cellular cytotoxicity: relevance for immunotherapy of carcinomas | Q39708585 | ||
| T cell immunoglobulin- and mucin-domain-containing molecule-3 (Tim-3) mediates natural killer cell suppression in chronic hepatitis B. | Q39743569 | ||
| Maturation pathways of dendritic cells determine TAP1 and TAP2 levels and cross-presenting function | Q39824406 | ||
| Role of polymorphic Fc gamma receptor IIIa and EGFR expression level in cetuximab mediated, NK cell dependent in vitro cytotoxicity of head and neck squamous cell carcinoma cells | Q39868562 | ||
| Immunoglobulin G fragment C receptor polymorphisms and clinical efficacy of trastuzumab-based therapy in patients with HER-2/neu-positive metastatic breast cancer. | Q40001571 | ||
| Antibody-dependent cellular cytotoxicity mediated by cetuximab against lung cancer cell lines | Q40164557 | ||
| Natural killer cells produce T cell-recruiting chemokines in response to antibody-coated tumor cells | Q40333010 | ||
| CD16 polymorphisms and NK activation induced by monoclonal antibody-coated target cells. | Q40383762 | ||
| Nimotuzumab with chemoradiation confers a survival advantage in treatment-naïve head and neck tumors over expressing EGFR. | Q42474675 | ||
| HER-2/neu-specific monoclonal antibodies collaborate with HER-2/neu-targeted granulocyte macrophage colony-stimulating factor secreting whole cell vaccination to augment CD8+ T cell effector function and tumor-free survival in Her-2/neu-transgenic m | Q42798418 | ||
| Interleukin 2 activation of natural killer cells rapidly induces the expression and phosphorylation of the Leu-23 activation antigen | Q42939169 | ||
| CD137 ligand signaling induces human monocyte to dendritic cell differentiation | Q43672129 | ||
| Functional significance of the activation-associated receptors CD25 and CD69 on human NK-cells and NK-like T-cells | Q44390045 | ||
| Phase II study of nimotuzumab, a humanized monoclonal anti-epidermal growth factor receptor (EGFR) antibody, in patients with locally advanced or metastatic pancreatic cancer | Q44656784 | ||
| Structural basis for inhibition of the epidermal growth factor receptor by cetuximab | Q45345151 | ||
| Impact of Fc{gamma}RIIa-Fc{gamma}RIIIa polymorphisms and KRAS mutations on the clinical outcome of patients with metastatic colorectal cancer treated with cetuximab plus irinotecan. | Q46151045 | ||
| CD137 Stimulation Enhances Cetuximab-Induced Natural Killer: Dendritic Cell Priming of Antitumor T-Cell Immunity in Patients with Head and Neck Cancer | Q50043038 | ||
| A novel approach to induce human DCs from monocytes by triggering 4-1BBL reverse signaling. | Q54726334 | ||
| Antiproliferative, antiangiogenic and proapoptotic activity of h-R3: A humanized anti-EGFR antibody | Q74802802 | ||
| CD69 is a stimulatory receptor for natural killer cell and its cytotoxic effect is blocked by CD94 inhibitory receptor | Q78127360 | ||
| Cetuximab induce antibody-dependent cellular cytotoxicity against EGFR-expressing esophageal squamous cell carcinoma | Q79346005 | ||
| Nimotuzumab provides survival benefit to patients with inoperable advanced squamous cell carcinoma of the head and neck: a randomized, open-label, phase IIb, 5-year study in Indian patients | Q87419417 | ||
| Dual Faces of IFNγ in Cancer Progression: A Role of PD-L1 Induction in the Determination of Pro- and Antitumor Immunity | Q89066168 | ||
| P921 | main subject | dendritic cell | Q506253 |
| head and neck cancer | Q1783924 | ||
| head and neck carcinoma | Q18554836 | ||
| neck cancer | Q18966654 | ||
| P304 | page(s) | 382 | |
| P577 | publication date | 2017-06-19 | |
| P1433 | published in | Frontiers in Pharmacology | Q2681208 |
| P1476 | title | Nimotuzumab Induces NK Cell Activation, Cytotoxicity, Dendritic Cell Maturation and Expansion of EGFR-Specific T Cells in Head and Neck Cancer Patients | |
| P478 | volume | 8 |
| Q64102265 | Rationale for Combining Radiotherapy and Immune Checkpoint Inhibition for Patients With Hypoxic Tumors |
| Q49887925 | Receptor tyrosine kinases (RTKs) in breast cancer: signaling, therapeutic implications and challenges |
| Q90290848 | The Efficacy and Safety of Anti-epidermal Growth Factor Receptor Monoclonal Antibodies in Nasopharyngeal Carcinoma: Literature-based Meta-analyses |
| Q98466288 | The Latest Battles Between EGFR Monoclonal Antibodies and Resistant Tumor Cells |
| Q90176787 | Unleashing Natural Killer Cells in the Tumor Microenvironment-The Next Generation of Immunotherapy? |
Search more.